The results of a study identify a correlation between the presence of biomarkers in the blood, known as micro RNAs (miRNAs), and the development of severe osteoarthritis (OA) of the knee or hip joint.
The study was presented at the European League Against Rheumatism Annual Congress (EULAR 2014). The findings suggest that miRNAs may be used as biomarkers to predict severe OA disease in individuals.
Preventative measures and early treatments are considered to be the most effective way of managing OA, but to date there has been no way of identifying the disease early on.
OA is a common musculoskeletal disorder affecting 10% of the world's population. It is characterised by pain and stiffness in the joints and is one of the top ten most disabling diseases in developed countries, posing a major cause of knee or hip replacements. Disability from the disease has a great impact on individuals, healthcare systems and society, contributing to loss of productivity and inability to work. The average total annual cost of OA per patient is between 1,330 and 10,452 across Europe.With risk factors including advancing age and obesity, the burden of the disease is expected to grow.
This study screened existing serum samples of people with OA, through which they identified three potential miRNA markers. 816 patients were followed over 15 years and measured for the presence of the 374 miRNAs and the occurrence of OA, using joint replacement (known as arthroplasty), as a definitive outcome of severe OA in the knee or hip. Of the 816 patients, 67 patients had one or more total joint replacements for severe knee or hip OA. The results of serum analysis showed a correlation between severe knee or hip OA and three miRNA molecules known as let-7e, miR-454 and miR-885-5p. These results indicate those miRNAs could be used as biomarkers to predict severe OA.
This is the first study to identify differentially expressed miRNAs in osteoarthritis patients necessitating arthroplasty, in a large population-based cohort using the well-defined Bruneck cohort.